These findings suggest that MALT1 may be a novel promising therapeutic target for T-ALL treatment and support the potential of MI-2 or other MALT1 inhibitors to clinical trials in T-ALL. The gene discussed is MALT1; the disease is acute lymphoblastic leukemia.